PPAR γ activation by pioglitazone does not suppress cravings for alcohol, and is associated with a risk of myopathy in treatment seeking alcohol dependent patients: a randomized controlled proof of principle study

ConclusionsBoth safety and efficacy biomarker data suggest that pioglitazone lacks potential as a medication for the treatment of alcohol dependence.Clinical trial registrationNCT01631630

Source: Psychopharmacology - July 10, 2020 Category: Psychiatry Source Type: research